MARKET

OCGN

OCGN

Ocugen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3751
-0.0180
-4.58%
Closed 19:52 12/11 EST
OPEN
0.3949
PREV CLOSE
0.3931
HIGH
0.4085
LOW
0.3730
VOLUME
4.53M
TURNOVER
--
52 WEEK HIGH
34.80
52 WEEK LOW
0.2350
MARKET CAP
4.58M
P/E (TTM)
-0.0622
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of OCGN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

OCGN News

  • Ocugen Announces Completion of 50% of Enrollment of its Phase 3 Clinical Trial for ocular GVHD
  • GlobeNewswire.2d ago
  • The future of the US wireless industry in limbo as T-Mobile and Sprint begin battle to win merger approval
  • CNBC.com.3d ago
  • 5 Safe And Cheap Dividend Stocks To Invest (December 2019)
  • Seeking Alpha - Article.4d ago
  • Top Holdings Of Dividend ETFs (Part 2: The Top 7 By Sector In November 2019)
  • Seeking Alpha - Article.4d ago

More

Industry

Pharmaceuticals
+0.17%
Pharmaceuticals & Medical Research
+0.07%

Hot Stocks

Name
Price
%Change

About OCGN

Ocugen, Inc., formerly Histogenics Corporation is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of therapies for eye diseases. The Company offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The Company is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The Company is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).
More

Webull offers Ocugen Inc (OCGN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.